Application of gypenoside XLV Ed in preparation of hepatoma resisting medicine

A gypenoside and anti-liver cancer technology, applied in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc., to achieve the effects of promoting death, inhibiting growth, and good development and application prospects

Active Publication Date: 2014-12-10
XIAMEN TASMAN BIO TECH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are only a handful of domestic reports on Gypenoside XLV Ed, and only Chinese invention patent CN103243147A shows that Gypenoside XLV Ed can be extracted from Gynostemma pentaphyllum, and Gypenoside XLV Ed with a concentration of 150 μg / ml has 65% growth in yeast cells inhibition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gypenoside XLV Ed in preparation of hepatoma resisting medicine
  • Application of gypenoside XLV Ed in preparation of hepatoma resisting medicine
  • Application of gypenoside XLV Ed in preparation of hepatoma resisting medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The following embodiments will further illustrate the present invention in conjunction with the accompanying drawings.

[0014] 1. Determination of cytotoxic activity

[0015] Determination method: prepare the sample to be tested (positive control ginsenoside IH901, gypenoside XLV Ed precursor gypenoside total saponins, gypenoside XLV Ed) to a concentration of 50mg / mL with DMSO (dimethyl sulfoxide), centrifuge at 12000rpm for 10min , aspirate the supernatant as the sample determination solution. The human liver cancer cells SMMC7721 and Bel7402 in the logarithmic growth phase were seeded into 96-well plates according to 5000 cells per well, in 5% CO 2 Incubate at 37°C for 24 hours in an incubator, and then add 200 μL of a series of medium containing different concentration gradient assay samples to continue the cultivation. Both the drug-dosed group and the control group were provided with 4 duplicate wells, and each plate was provided with 8 blank control wells (no c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of gypenoside XLV Ed in preparation of a hepatoma resisting medicine, and relates to gypenoside. The gypenoside XLV Ed is named as 2-hydroxy-3-O-beta-D-glucopyranose-20(S)-protopanoxadiol-20-O-beta-D-glucopyranoside which is of white powder and has a molecular formula of C42H72O14 and a molecular weight of 800. The gypenoside XLV Ed can be obtained by carrying out separation and purification step by step by utilizing a method of enzymatic conversion of gynostemma total saponins. The gypenoside XLV Ed is simple in preparation method and low in cost. By taking the hepatoma as a model, the testing of the in-vitro liver cancer resisting model shows that the gypenoside XLV Ed has an obvious effect for inhibiting the growth of human hepatoma cells SMMC7721 and Bel7402 and can used for degrading DNA in the human hepatoma cells Bel7402 into tiny fragments to promote the death of the human hepatoma cells so as to inhibit the growth of the hepatoma. Thus, the gypenoside XLV Ed can be applied to the preparation of the hepatoma resisting medicine.

Description

technical field [0001] The invention relates to gypenoside, in particular to the application of gypenoside XLV Ed in the preparation of anti-liver cancer drugs. Background technique [0002] Tumor is a common and frequently-occurring disease, among which malignant tumor (Malignant Tumor, Cancer) is the most serious disease that endangers human health. According to the data released by the Ministry of Health of my country, the death rate of malignant tumors in both rural and urban populations in China ranked first in 2006. Among many malignant tumors, liver cancer (Hetatocellular Carcinoma, HCC) is the most difficult to treat. So far, there is still a lack of ideal therapeutic drugs. The mortality rate of patients remains high all year round, and the 5-year survival rate is low. 42.5% of newly discovered liver cancer patients in the world occur in China every year, and most of them are 40-50 years old. In the early stage of liver cancer, there are generally no clinical symp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00C07J17/00
Inventor 明艳林郑志忠陈良华刘韶松郑国华童庆宣
Owner XIAMEN TASMAN BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap